Literature DB >> 23884581

Elevated risk of opportunistic viral infection in patients with Crohn's disease during biological therapies: a meta analysis of randomized controlled trials.

Xiaobing Wang1, Feng Zhou, Junzhang Zhao, Rui Zhou, Meifang Huang, Jin Li, Wei Wang, Shufang Xu, Bing Xia.   

Abstract

BACKGROUND: Biological agents have been widely used in the treatment of Crohn's disease (CD). These drugs carry the risk of excessive immunosuppression, indicating possible opportunistic infections including opportunistic viral infections, but no meta analysis has ever focused on this issue.
PURPOSE: To evaluate whether there is an association between biological agents therapy and the risk of opportunistic viral infections and serious infections in patients with CD.
METHODS: A search of online databases was performed and literature selection was carried out according to the inclusion and exclusion criteria by reading titles, abstracts and full texts. Study heterogeneity and publication bias were assessed. Whether to choose a fixed effects model or a random effects model depended on the result of heterogeneity test.
RESULTS: There was a statistical significance in opportunistic viral infection events between the biological agents group and the placebo group. However, our analysis didn't observe statistically significant differences between the two groups when combined analyses were carried out for herpes zoster and herpes simplex separately. A risk trend in the biological agents group was observed in the analysis for herpes zoster. More analyses aimed at the outcome measures and including influenza and serious infection were carried out separately, but no statistical significance was found in them.
CONCLUSION: Biological agents use might increase the risk of opportunistic viral infections in patients with CD, but not the risk of herpes simplex and serious infections. More randomized controlled trials (RCTs) are needed to draw the conclusion of whether they could elevate the risk of herpes zoster.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23884581     DOI: 10.1007/s00228-013-1559-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  54 in total

1.  A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.

Authors:  S E Plevy; C J Landers; J Prehn; N M Carramanzana; R L Deem; D Shealy; S R Targan
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

Review 2.  Role of conventional therapies in the era of biological treatment in Crohn's disease.

Authors:  Paolo Gionchetti; Carlo Calabrese; Rosy Tambasco; Ramona Brugnera; Giulia Straforini; Giuseppina Liguori; Giulia Spuri Fornarini; Donatella Riso; Massimo Campieri; Fernando Rizzello
Journal:  World J Gastroenterol       Date:  2011-04-14       Impact factor: 5.742

3.  Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.

Authors:  William J Sandborn; Stefan Schreiber; Brian G Feagan; Paul Rutgeerts; Ziad H Younes; Ralph Bloomfield; Geoffroy Coteur; Juan Pablo Guzman; Geert R D'Haens
Journal:  Clin Gastroenterol Hepatol       Date:  2011-05-13       Impact factor: 11.382

4.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

5.  PI3K p110beta positively regulates lipopolysaccharide-induced IL-12 production in human macrophages and dendritic cells and JNK1 plays a novel role.

Authors:  Mitsuyoshi Utsugi; Kunio Dobashi; Akihiro Ono; Tamotsu Ishizuka; Shin-ichi Matsuzaki; Takeshi Hisada; Yasuo Shimizu; Tadayoshi Kawata; Haruka Aoki; Yosuke Kamide; Masatomo Mori
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

6.  Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.

Authors:  E H S Choy; B Hazleman; M Smith; K Moss; L Lisi; D G I Scott; J Patel; M Sopwith; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2002-10       Impact factor: 7.580

7.  Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.

Authors:  Frank M Ruemmele; Alain Lachaux; Jean-Pierre Cézard; Alain Morali; Chantal Maurage; Jean-Louis Giniès; Sheila Viola; Olivier Goulet; Thierry Lamireau; Michèle Scaillon; Anne Breton; Jacques Sarles
Journal:  Inflamm Bowel Dis       Date:  2009-03       Impact factor: 5.325

8.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

Authors:  C S J Probert; S D Hearing; S Schreiber; T Kühbacher; S Ghosh; I D R Arnott; A Forbes
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

9.  The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

Authors:  Michael Hutchinson; Ludwig Kappos; Peter A Calabresi; Christian Confavreux; Gavin Giovannoni; Steven L Galetta; Eva Havrdova; Fred D Lublin; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; Richard A Rudick; William H Stuart; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

10.  Interleukin-23 drives intestinal inflammation through direct activity on T cells.

Authors:  Philip P Ahern; Chris Schiering; Sofia Buonocore; Mandy J McGeachy; Dan J Cua; Kevin J Maloy; Fiona Powrie
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

View more
  3 in total

1.  Regulatory role of NKG2D+ NK cells in intestinal lamina propria by secreting double-edged Th1 cytokines in ulcerative colitis.

Authors:  Fan Wang; Pai-Lan Peng; Xue Lin; Ying Chang; Jing Liu; Rui Zhou; Jia-Yan Nie; Wei-Guo Dong; Qiu Zhao; Jin Li
Journal:  Oncotarget       Date:  2017-10-30

Review 2.  COVID-19 and Inflammatory Bowel Diseases: Risk Assessment, Shared Molecular Pathways, and Therapeutic Challenges.

Authors:  Iolanda Valentina Popa; Mircea Diculescu; Cătălina Mihai; Cristina Cijevschi-Prelipcean; Alexandru Burlacu
Journal:  Gastroenterol Res Pract       Date:  2020-07-10       Impact factor: 2.260

3.  Patients With Inflammatory Bowel Diseases Are at Higher Risk for Meningitis.

Authors:  Bharati Kochar; Yue Jiang; Millie D Long
Journal:  J Clin Gastroenterol       Date:  2021-04-01       Impact factor: 3.174

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.